Key points A 40-year-old woman presented to her family physician with a new subcutaneous mass in the right lower quadrant of her abdomen, along with nonspecific systemic symptoms, including occasional ...

Knowing where and how to inject GLP-1s can help ensure you are safely and effectively using the medication. Common sites ...

This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...

Injection site reactions are the most common side effect of Emgality. The most frequent injection site reaction is pain. But there are steps you can take to help prevent or reduce pain from Emgality ...

Injections deliver liquid medications, fluids, or nutrients directly into a person’s body. Different types of injections include intravenous, intramuscular, subcutaneous, intraosseous, and intradermal ...

Caliway has completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA for CBL-514, the world's first investigational drug for large-area subcutaneous fat reduction developed under the 505(b)(1) ...

NEW TAIPEI CITY, Jan. 23, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announces that Australian Bellberry HREC has approved Caliway's application to initiate CBL-514's Pivotal Phase 3 ...